Direct vascular effects of HMG-CoA reductase inhibitors

Trends in Cardiovascular Medicine

Volumn 10, Issue 4, 2000, Pages 143-148

  Laufs, Ulrich ^a   Liao, James K ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Vascular Medicine Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVALONIC ACID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN KINASE; RETINOBLASTOMA PROTEIN; RHO FACTOR; STATINE DERIVATIVE;

BLOOD VESSEL WALL; BRAIN INFARCTION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HEART INFARCTION; HUMAN; ISOPRENYLATION; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE;

EID: 0034471646     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(00)00044-X     Document Type: Review

References (47)

1. Bacterial toxins that target Rho proteins
2. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
3. Comparison of properties of four inhibitors of 3-hydroxy-3- methylglutaryl-coenzyme A reductase
4. Cell cycle progression; new therapeutic target for vascular proliferative disease
5. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease
6. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4
7. HMG-CoA reductase inhibitor therapy and stroke risk reduction; an analysis of clinical trials data
8. Dual role of nitric oxide in focal cerebral ischemia
9. Cdk inhibitors; on the threshold of checkpoints and development
10. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
11. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins
12. Regulation of the mevalonate pathway
13. Rho GTPases and the actin cytoskeleton
14. Cellular and molecular mechanisms of endothelial cell dysfunction
15. Translational control of p27Kip1 accumulation during the cell cycle
16. Hypertension in mice lacking the gene for endothelial nitric oxide synthase
17. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine
18. Control of signal transduction and morphogenesis by Ras
19. Serum cholesterol in young men and subsequent cardiovascular disease
20. Effect of pravastatin on outcomes after cardiac transplantation
21. E2F and the molecular mechanisms of early cell-cycle control
22. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
23. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
24. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
25. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
26. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts
27. Endothelium and acute coronary syndromes
28. Molecular biology of atherosclerosis
29. Inhibition of the mevalonate pathway; benefits beyond cholesterol reduction?
30. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group
31. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance
32. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
33. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
34. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
35. The cell cycle kinases
36. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators
37. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Simvastatin Survival Study (4S)
38. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
39. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
40. Cancer cell cycles
41. Changes in risk factors and the decline in mortality from cardiovascular disease
42. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
43. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
44. Rho GTPases and signaling networks
45. The retinoblastoma protein and cell cycle control
46. p21 is a universal inhibitor of cyclin kinases
47. What is the restriction point?